---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-010569"
form_type: "8-K"
ticker: "CSBR"
cik: "0000771856"
company_name: "CHAMPIONS ONCOLOGY, INC."
filed_at: "2024-03-12T23:59:59+00:00"
generated_at: "2026-06-04T23:32:28.327213+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Champions Oncology Q3 revenue down 6% to $12.0M; operating loss widens to $2.6M

## Summary
- Q3 FY2024 revenue $12.0M, down from $12.8M YoY; gross margin fell to 34.7% from 39.7%.
- Operating loss of $2.6M vs $2.5M a year ago; adjusted EBITDA loss of $1.7M.
- Nine-month revenue $36.2M, down 11.4%; operating loss of $7.1M vs $2.7M loss YoY.
- Cash and equivalents $4.5M at quarter end; no debt outstanding.
- Company seeking capital for Corellia AI subsidiary; two lead targets progress toward licensing.

## SEC filing metadata
- accession: 0001628280-24-010569
- form_type: 8-K
- ticker: CSBR
- cik: 0000771856
- company_name: CHAMPIONS ONCOLOGY, INC.
- filed_at: 2024-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/771856/000162828024010569/0001628280-24-010569-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/771856/000162828024010569/csbr-20240312.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-010569
- JSON: https://secwatch.observer/filing/0001628280-24-010569.json
- Plain text: https://secwatch.observer/filing/0001628280-24-010569.txt

## Key facts
- Earnings Releases
  CHAMPIONS ONCOLOGY, INC. reported third quarter ended January 31, 2024 results: revenue $12.0 million.
  - Period: third quarter ended January 31, 2024
  - Revenue: $12.0 million
  - Result: reported results
  source text: Champions Oncology Reports Quarterly Revenue of $12.0 Million
  evidence_url: https://www.sec.gov/Archives/edgar/data/771856/000162828024010569/0001628280-24-010569-index.htm
- Earnings Releases
  CHAMPIONS ONCOLOGY, INC. reported first nine months of fiscal 2024 results: revenue $36.2 million.
  - Period: first nine months of fiscal 2024
  - Revenue: $36.2 million
  - Result: reported results
  source text: For the first nine months of fiscal 2024, revenue decreased 11.4% to $36.2 million compared to $40.8 million for the first nine months of fiscal 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/771856/000162828024010569/0001628280-24-010569-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.